Fig. 1: Generation of USP7i-resistant cells derived from CHP-212 cells.
From: USP7 V517F mutation as a mechanism of inhibitor resistance
a Schematic representation of the generation of USP7-797-resistant variants. CHP-212 cells were exposed to 10 μM USP7-797 for 5 days, refreshing with drug-free media, and repeating for 5 cycles. Six drug-resistant monoclonal cells (R1-R6) were selected. b Dose-response curves of USP7i USP7-797 and FT671 in parental and resistant cells following a 5-day exposure. Left panel, the IC50 values of USP7-797 and FT671 were determined using SRB assays. Data are presented as mean ± SD (n = 3 technical replicates; 3 independent experiments). Right panel, the resistance factor (RF) was calculated by comparing the average IC50 value of the resistant cells to that of the parental cells. c The chemical structure and dose-response curves of another USP7i GNE-6640 in the parental and resistant cells. Cells were treated with GNE-6640 for 5 days, and cell viability was assessed using SRB assays. Data are presented as mean ± SD (n = 3 technical replicates; 3 independent experiments). d The IC50 values of MLN4924, KSQ4279, Adriamycin, Bortezomib, TAXOL, and VCR in parental and resistant cells were determined using SRB assays following 3 days exposure. Data are presented as mean ± SD (n = 3 technical replicates; 3 independent experiments).
